Test Price
450 AED✅ Home Collection Available
Immunohistochemistry Carbonic Anhydrase-9 (CA-9) Test in UAE | 450 AED | DHA Licensed
Executive Summary & Core Metrics
Executive Summary: The Immunohistochemistry Carbonic Anhydrase-9 (CA-9) Test is a specialised tissue-based assay that detects CA-9 protein expression—a validated hypoxia-inducible biomarker critically implicated in clear cell Renal Cell Carcinoma (ccRCC), urothelial carcinoma, and other hypoxic tumour microenvironments. This test is conducted under DHA oversight with ISO 9001:2015 accredited processes, delivering 99.9% diagnostic sensitivity through digital pathology review.
Test Overview & Methodology
The Carbonic Anhydrase-9 (CA-9) immunohistochemistry test detects a hypoxia-regulated protein predominantly expressed in clear cell Renal Cell Carcinoma (ccRCC), serving as a critical differential diagnostic marker to distinguish ccRCC from other renal tumour subtypes with high specificity. CA-9 overexpression is driven by HIF-1α pathway activation, commonly resulting from VHL gene inactivation, and its membranous staining pattern provides definitive evidence for classification.
| Feature | Our CA-9 IHC Test | Standard Histopathology |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity via ISO-Accredited IHC Platform | Morphology-Only Assessment (~85–90% Sensitivity) |
| Methodology | Monoclonal Antibody IHC with DAB Chromogen Detection & Digital Pathology Review | H&E Staining with Manual Microscopy |
| Turnaround Time | 5–7 Days (Tissue Biopsy / Large Complex Cases) | 7–14 Days (Routine Workflow) |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (DHA License: 61713011, Specialist Diagnostic Radiology) shares:
"A precise CA-9 interpretation requires correlating the immunohistochemical staining pattern with the complete histomorphology and clinical context. I personally review each case to ensure that the distinction between clear cell RCC and its mimics is accurately documented, as this directly influences targeted therapy decisions and surgical planning. Remember, the result is a piece of the puzzle—your oncologist will integrate it with imaging and lab data to guide your treatment."
Medication Advisory
⚠ Do not discontinue any prescribed medication without consulting your doctor. No medication adjustments are required specifically for CA-9 immunohistochemistry testing; however, any changes to your current therapeutic regimen must be directed exclusively by your supervising oncologist or treating physician.
Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Elective Biopsy (Hospital Extraction Only):
- Known bleeding diathesis or current therapeutic anticoagulation with INR > 2.5
- Platelet count below 50,000/µL (verified within 72 hours)
- Active cutaneous or systemic infection with fever > 38.3°C
- Inability to provide informed consent per Federal Decree-Law No. 4 of 2016 on Medical Liability
- Pregnancy (first trimester) — requires specialist clearance
Emergency Red Flags — Seek Immediate Medical Attention:
- Excessive or uncontrolled bleeding from the biopsy site persisting > 30 minutes
- Sudden onset of dyspnea, chest pain, or haemodynamic instability post-procedure
- Signs of acute surgical site infection: purulent discharge, spreading erythema, or escalating pain
- Temperature spike > 38.5°C within 48 hours of tissue sampling
- Any new neurological deficit or altered consciousness
Patient FAQ & Clinical Guidance
1. What is the CA-9 immunohistochemistry test used for in cancer diagnosis?
Answer: The Carbonic Anhydrase-9 (CA-9) immunohistochemistry test is a specialised tissue-based assay that detects a hypoxia-regulated protein predominantly expressed in clear cell Renal Cell Carcinoma (ccRCC), serving as a critical differential diagnostic marker to distinguish ccRCC from other renal tumour subtypes with high specificity. CA-9 overexpression is driven by HIF-1α pathway activation, commonly resulting from VHL gene inactivation, and its membranous staining pattern on IHC provides the surgical pathologist with definitive evidence for classifying a renal mass as ccRCC versus papillary RCC, chromophobe RCC, or oncocytoma — a distinction that directly influences surgical margin planning, targeted therapy selection (including tyrosine kinase inhibitors and mTOR inhibitors), and clinical trial eligibility.
2. How should I prepare for the tissue sample collection for this test?
Answer: Tissue sample collection for CA-9 immunohistochemistry requires submission of your tumour specimen as either a Formalin-Fixed Paraffin-Embedded (FFPE) block or fresh biopsy tissue immediately placed in 10% neutral buffered formalin-saline, shipped at controlled room temperature, and must be accompanied by your complete histopathology report, precise biopsy site documentation, and full clinical history to ensure accurate immunohistochemical interpretation by the surgical pathologist. No fasting or dietary restrictions are necessary; however, you must inform your healthcare provider of all anticoagulant or antiplatelet medications you are taking at least five days prior to any planned biopsy procedure.
3. What does a negative CA-9 result mean for my diagnosis?
Answer: A negative CA-9 immunohistochemistry result does not exclude malignancy; it redirects the diagnostic workup toward alternative renal tumour entities such as papillary or chromophobe RCC, each requiring fundamentally different management pathways. Your oncologist will correlate the negative staining with the tumour morphology, imaging findings, and additional immunohistochemical panels to arrive at a precise diagnosis and tailor treatment accordingly.
UAE Regulatory & Data Privacy Adherence
This service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All tissue samples are processed in ISO 9001:2015-certified facilities under strict confidentiality protocols. Results must be correlated with clinical findings by a DHA-licensed physician. DHA Facility License: 1143.
Clinical & Logistical Metadata
| Test Name | Carbonic Anhydrase-9 (CA-9) Immunohistochemistry |
| Price (AED) | 450 AED |
| Turnaround Time | 5–7 Days (Tissue Biopsy / Large Complex Cases) |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Fresh Biopsy Tissue in 10% Neutral Buffered Formalin |
| Methodology Used | Monoclonal Antibody Immunohistochemistry (IHC) with DAB Chromogen Detection and Digital Pathology Review |
| ICD-10-CM Code | C64.9 |
| LOINC Code | 98205-9 |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians